Should Monitoring of Fibroblast Growth Factor‐23 Levels in Dialysis Patients Be a Part of Routine Clinical Practice?

D’Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805–809, 1998 14. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753–761, 2000 15. Terry AH, Orrock J, Meikle AW: Comparison of two-third-generation parathyroid hormone assays. Clin Chem 49:336–337, 2003 16. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG: Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 68:1206–1214, 2005 17. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H: Similar predictive value of bone turnover using firstand second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801–1808, 2003 18. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460–1468, 2001 19. Ankrah-Tetteh T, Wijeratne S, Swaminathan R: Intraindividual variation in serum thyroid hormones, parathyroid hormone and insulin-like growth factor-1. Ann Clin Biochem 45:167–169, 2008 20. Gardham C, Stevens PE, Delaney MP, LeRoux M, Coleman A, Lamb EJ: Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 5:1261–1267, 2010 21. Cantor T, Yang Z, Caraiani N, Ilamathi E: Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 52:1771–1776, 2006 22. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345–350, 2006 23. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure–an evolving disorder. Kidney Int 43:436–442, 1993 24. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836–844, 1995 25. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145–150, 1992 26. Barreto FC, Barreto DV, Moyses RMA, Neves KR, Canziani MEF, Draibe SA, Jorgetti V, Carvalho AB: K//DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73:771–777, 2008 27. Gal-Moscovici A, Popovtzer MM: New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol 63:284–289, 2005 28. Palmer SC, Hayen A, Macaskill P: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305:1119–1127, 2011 29. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R: Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 19:1379–1388, 2008 30. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K//DOQI[trade] bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760–771, 2005 31. Effect of Cinacalcet on Cardiovascular Disease in Patients: Undergoing dialysis. N Engl J Med 367:2482–2494, 2012 32. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 7:506–512, 1996